Revelation Biosciences posts updated presentation

Revelation Biosciences, Inc. furnished an updated corporate presentation, dated June 1, 2026, and made it available to the public on its website.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Revelation Biosciences, Inc. furnished an updated corporate presentation, dated June 1, 2026, and made it available to the public on its website. The presentation is attached as Exhibit 99.1 to this report under Item 8.01 Other Information and is incorporated by reference.

The company clarifies that the materials in Item 8.01 and Exhibit 99.1 are being furnished, not filed, so they are not subject to certain Exchange Act liabilities and are only incorporated into other filings if specifically referenced. Item 9.01 lists Exhibit 99.1 and an Inline XBRL cover page file as Exhibit 104.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Terms

corporate presentation, Emerging growth company, Inline XBRL, Item 8.01 Other Information, +1 more

5 terms

corporate presentation financial

"On June 1, 2026, Revelation Biosciences, Inc. ... prepared and released an updated corporate presentation"

Emerging growth company regulatory

"Emerging growth company Item 8.01 Other Information."

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Inline XBRL technical

"104 | | Cover Page Interactive Data File (embedded with the Inline XBRL document)"

Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.

Item 8.01 Other Information regulatory

"Emerging growth company Item 8.01 Other Information."

Exhibit 99.1 regulatory

"Exhibit 99.1 | | Corporate Presentation, dated June 1, 2026"

Exhibit 99.1 is a label used in regulatory filings to identify a specific attached document, most often a company press release or investor presentation filed with securities regulators. For investors it matters because it marks an official, contemporaneous source of information directly tied to a filing—like the original news article pinned to a legal record—so traders and analysts treat it as an authoritative statement that can move a stock or clarify a company’s situation.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Revelation Biosciences (REVB) disclose in this Form 8-K?

Revelation Biosciences furnished an updated corporate presentation dated June 1, 2026. The presentation is provided to investors as Exhibit 99.1 and is also available on the company’s website, offering an overview of its current corporate information and positioning.

When is the Revelation Biosciences (REVB) corporate presentation dated?

The updated Revelation Biosciences corporate presentation is dated June 1, 2026. This date appears in both the description of Item 8.01 Other Information and the exhibit index, where the presentation is identified as Exhibit 99.1 to the current report.

How is the Revelation Biosciences (REVB) corporate presentation treated under SEC rules?

The corporate presentation in Item 8.01 and Exhibit 99.1 is being furnished, not filed, under the Exchange Act. This means it is not subject to Section 18 liabilities and is only incorporated into other Securities Act or Exchange Act filings if expressly referenced.

Where can investors access Revelation Biosciences’ updated corporate presentation?

Investors can access Revelation Biosciences’ updated corporate presentation on the company’s website. A copy is also attached to the current report as Exhibit 99.1, giving the public two direct avenues to review the same investor-facing materials.

What exhibits are included in this Revelation Biosciences (REVB) 8-K filing?

The filing lists two exhibits: Exhibit 99.1, which is the corporate presentation dated June 1, 2026, and Exhibit 104, which is the cover page interactive data file embedded within the Inline XBRL document accompanying the current report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/01/2026 - 05:26 PM

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     Date of Report (Date of earliest event reported): June 01, 2026

    

REVELATION BIOSCIENCES, INC.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-39603	84-3898466
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

4660 La Jolla Village Drive Suite 100
San Diego, California		92122
(Address of Principal Executive Offices)		(Zip Code)

     Registrant’s Telephone Number, Including Area Code: (650) 800-3717

    

     Not Applicable

    

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.001 per share	REVB	The Nasdaq Stock Market LLC
Redeemable warrants, each exercisable for a 1/201,600th share of common stock at an exercise price of $2,318,400 per share	REVBW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Information.

On June 1, 2026, Revelation Biosciences, Inc. (the “Company”) prepared and released an updated corporate presentation made available to the public. The corporate presentation can be found on the Company’s website. A copy of the presentation is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 8.01 and in Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.




Exhibit No.		Description
99.1		Corporate Presentation, dated June 1, 2026
104		Cover Page Interactive Data File (embedded with the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


		REVELATION BIOSCIENCES, INC.

Date: June 1, 2026	By:	/s/ Chester S. Zygmont, III
		Chester S. Zygmont, III Chief Financial Officer (principal financial and accounting officer)